Ameriprise Financial Inc. Has $635,000 Stock Holdings in ClearPoint Neuro, Inc. (NASDAQ:CLPT)

Ameriprise Financial Inc. increased its holdings in ClearPoint Neuro, Inc. (NASDAQ:CLPT) by 7.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 41,316 shares of the company’s stock after purchasing an additional 2,742 shares during the period. Ameriprise Financial Inc. owned approximately 0.15% of ClearPoint Neuro worth $635,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. R Squared Ltd acquired a new position in ClearPoint Neuro in the fourth quarter worth about $32,000. AlphaQuest LLC acquired a new stake in shares of ClearPoint Neuro during the fourth quarter worth approximately $80,000. Tower Research Capital LLC TRC bought a new stake in shares of ClearPoint Neuro during the fourth quarter valued at approximately $93,000. ExodusPoint Capital Management LP bought a new stake in shares of ClearPoint Neuro during the fourth quarter valued at approximately $204,000. Finally, MGO One Seven LLC bought a new stake in shares of ClearPoint Neuro during the fourth quarter valued at approximately $269,000. Institutional investors and hedge funds own 30.08% of the company’s stock.

ClearPoint Neuro Stock Performance

CLPT opened at $12.66 on Wednesday. The firm’s fifty day moving average is $12.65 and its two-hundred day moving average is $14.24. The firm has a market cap of $354.34 million, a PE ratio of -18.35 and a beta of 1.03. ClearPoint Neuro, Inc. has a twelve month low of $5.11 and a twelve month high of $19.22.

ClearPoint Neuro (NASDAQ:CLPT) last posted its earnings results on Tuesday, May 13th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.07). The firm had revenue of $8.49 million during the quarter, compared to analyst estimates of $8.21 million. ClearPoint Neuro had a negative return on equity of 62.10% and a negative net margin of 59.64%. Equities analysts forecast that ClearPoint Neuro, Inc. will post -0.66 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently commented on CLPT. Stifel Nicolaus increased their price target on shares of ClearPoint Neuro from $19.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, April 1st. Wall Street Zen cut shares of ClearPoint Neuro from a “hold” rating to a “sell” rating in a research note on Thursday, May 22nd.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.